Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Study Title

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Teva Identifier

C38072/3083 | 2010-024006-35

ClinicalTrials.gov Identifier

NCT01285323

Study Status

Completed

Trial Condition(s)

Eosinophilic Asthma

Interventions

Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

12 Years to 75 Years

Trial Duration

03/01/2011 - 04/01/2014

Phase

Phase 3

Study Type

Interventional